New York Life Investment Management LLC acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 8,264 shares of the company’s stock, valued at approximately $924,000.
Several other hedge funds and other institutional investors have also modified their holdings of the business. GAMMA Investing LLC boosted its holdings in shares of Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after purchasing an additional 98 shares during the period. Fulcrum Asset Management LLP purchased a new position in Kymera Therapeutics during the third quarter valued at approximately $65,000. IFP Advisors Inc increased its stake in Kymera Therapeutics by 236.5% in the 3rd quarter. IFP Advisors Inc now owns 737 shares of the company’s stock valued at $82,000 after buying an additional 518 shares during the period. PNC Financial Services Group Inc. increased its stake in Kymera Therapeutics by 56.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after buying an additional 463 shares during the period. Finally, Nykredit A S acquired a new position in shares of Kymera Therapeutics in the second quarter worth $207,000.
Analyst Upgrades and Downgrades
KYMR has been the subject of a number of recent research reports. TD Cowen raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Raymond James Financial reissued an “outperform” rating on shares of Kymera Therapeutics in a research note on Thursday, October 29th. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price target for the company in a research note on Thursday, September 10th. BTIG Research increased their price objective on Kymera Therapeutics from $134.00 to $139.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. Finally, Wells Fargo & Company raised their price objective on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a research report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $139.16.
View Our Latest Research Report on KYMR
Insider Activity
In other news, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider owned 50,254 shares of the company’s stock, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the transaction, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. This represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 15.98% of the stock is currently owned by corporate insiders.
Kymera Therapeutics Stock Performance
Shares of Kymera Therapeutics stock opened at $127.57 on Monday. The company has a market cap of $10.89 billion, a price-to-earnings ratio of -35.24 and a beta of 2.04. The company’s fifty day simple moving average is $117.14 and its 200-day simple moving average is $99.35. Kymera Therapeutics, Inc. has a 1 year low of $62.13 and a 1 year high of $142.92.
Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). The firm had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The firm’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business earned ($0.94) earnings per share. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current fiscal year.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.
Featured Stories
- Five stocks we like better than Kymera Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report).
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
